Drug Trial Radar · NCT06372223
A Food Effect Study of SPH5030 Tablets.
Last checked: Nov 19, 2026Latest source record: Apr 17, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
16
Actual
Start
Mar 4, 2024
Primary completion
Mar 25, 2024
Study completion Mar 25, 2024
Sponsor
- Lead sponsor
- Shanghai Pharmaceuticals Holding Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Apr 17, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the food effect of SPH5030 tablets in healthy Chinese adult subjects.
Conditions
- Advanced Solid Tumor
Interventions
SPH5030Drug
SPH5030 tablets:400mg,orally, Dosing in the fasted state followed by fed dosing.
SPH5030Drug
SPH5030 tablets:400mg, orally, Dosing in the fed state followed by fasted dosing.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Peak Plasma Concentration (Cmax)Time frame: Approximately 2 months
- Peak time(Tmax)Time frame: Approximately 2 months
- Area under the plasma concentration versus time curve (AUC)Time frame: Approximately 2 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
West China Second Hospital ,Sichuan University
Chengdu, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.